SCI Abstract

search
+
Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment
Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment
The development of neoplasia involves a complex and continuous interplay between malignantly transformed cells and the tum...
In-depth organoid profiling of pancreatic cancer
In this Journal Club, Maeng and Ku discuss a study demonstrating that profiling drug responses in patient-derived organoid...
Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart
Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart
Immune-checkpoint inhibitors (ICIs) have revolutionized oncology, with nearly 50% of all patients with cancer eligible for...
The impact of sex on metastasis
The impact of sex on metastasis
Sex matters in metastasis, but it has received little attention in research. Here, we highlight the emerging and important...
Pre-empting drug resistance
Pre-empting drug resistance
Leighow et al. develop a strategy called the dual-switch selection gene drive platform, which enables the evolutionary dyn...
Enhancing cellular immunotherapies in cancer by engineering selective therapeutic resistance
Enhancing cellular immunotherapies in cancer by engineering selective therapeutic resistance
Adoptive cell therapies engineered to express chimeric antigen receptors (CARs) or transgenic T cell receptors (TCRs) to r...
Circular RNA in cancer
Circular RNA in cancer
Over the past decade, circular RNA (circRNA) research has evolved into a bona fide research field shedding light on the fu...
Rational combination of cancer therapies with PD1 axis blockade
Rational combination of cancer therapies with PD1 axis blockade
This poster explores rational combinations of immune checkpoint blockade of the PD1–PDL1 interaction with other ther...
Black voices in cancer research and oncology
Over the past few years, there has been an increasing realization that we need a more equal, diverse and inclusive culture...
Extrachromosomal DNA in cancer
Extrachromosomal DNA in cancer
Extrachromosomal DNA (ecDNA) has recently been recognized as a major contributor to cancer pathogenesis that is i...
Protein lipidation in cancer: mechanisms, dysregulation and emerging drug targets
Protein lipidation in cancer: mechanisms, dysregulation and emerging drug targets
Protein lipidation describes a diverse class of post-translational modifications (PTMs) that is regulated by over 40 enzym...
Catastrophic conformity
Catastrophic conformity
Recently published in Nature, Fan et al. demonstrate that accumulation of advanced glycation end-products in the extracell...
B-ring sterols to the rescue
B-ring sterols to the rescue
Two independent studies published in Nature implicate distal cholesterol biosynthesis in the regulation of ferroptosis and...
Immunogenic cell death in cancer: targeting necroptosis to induce antitumour immunity
Immunogenic cell death in cancer: targeting necroptosis to induce antitumour immunity
Most metastatic cancers remain incurable due to the emergence of apoptosis-resistant clones, fuelled by intratumour hetero...
New pathogen on the block
New pathogen on the block
Fu et al. provide data indicating a pathogenic role for Streptococcus anginosus in gastric cancer.
Trastuzumab: dreams, desperation and hope
Trastuzumab: dreams, desperation and hope
The story of trastuzumab begins with Axel Ullrich’s dedication to the concept that receptor tyrosine kinases must be...
Pressing defence
Pressing defence
In this study, Bansaccal et al. analyse why, at some skin locations, oncogene-expressing cells rarely progress to cancer a...
How chemokines organize the tumour microenvironment
How chemokines organize the tumour microenvironment
For our immune system to contain or eliminate malignant solid tumours, both myeloid and lymphoid haematopoietic cells must...
Targeting cancer cell dormancy
The field of tumour dormancy, originally defined as a clinical phenomenon of late recurrence after a long, apparently dise...
Fcγ receptors and immunomodulatory antibodies in cancer
Fcγ receptors and immunomodulatory antibodies in cancer
The discovery of both cytotoxic T lymphocyte-associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) as neg...
Removing barriers to address sex differences in anticancer drug toxicity
Removing barriers to address sex differences in anticancer drug toxicity
Despite the compelling evidence for greater toxicity in female patients, sex-specific anticancer treatment strategies are ...
Lighting up cancer initiation with mutant p53 reporters
In this Tools of the Trade article, Xiwen Tang describes the development of in vivo reporters detecting mutant p53 at the ...
The dynamic role of platelets in cancer progression and their therapeutic implications
The dynamic role of platelets in cancer progression and their therapeutic implications
Systemic antiplatelet treatment represents a promising option to improve the therapeutic outcomes and therapeutic efficacy...
UXS1: a sweet spot for cell death
UXS1: a sweet spot for cell death
Enzymes that produce metabolites specifically required by cancer cells have become attractive targets for therapy. Recentl...
Eph receptors and ephrins in cancer progression
Eph receptors and ephrins in cancer progression
Evidence implicating Eph receptor tyrosine kinases and their ephrin ligands (that together make up the ‘Eph...
Understanding and addressing race disparities in childhood cancer outcomes
Vulnerable populations remain disproportionately at risk for inferior childhood cancer outcomes. Here, I outline the scope...
Translating tumour immunity control
In this Journal Club, Hajj discusses a study demonstrating that oncogene activation modulates immune control through both ...
The microbiome as a determinant of racial and ethnic cancer disparities
The microbiome as a determinant of racial and ethnic cancer disparities
 People from minority racial and ethnic groups continue to experience disproportionate cancer incidences and canc...
How protons pave the way to aggressive cancers
How protons pave the way to aggressive cancers
Cancers undergo sequential changes to proton (H+) concentration and sensing that are consequences of the disease and facil...
Metabolic pathway analysis using stable isotopes in patients with cancer
Metabolic pathway analysis using stable isotopes in patients with cancer
Metabolic reprogramming is central to malignant transformation and cancer cell growth. How tumours use nutrients and the r...
Load More
format_indent_increase